ECSP13012770A - Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina - Google Patents

Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina

Info

Publication number
ECSP13012770A
ECSP13012770A ECSP13012770A ECSP13012770A EC SP13012770 A ECSP13012770 A EC SP13012770A EC SP13012770 A ECSP13012770 A EC SP13012770A EC SP13012770 A ECSP13012770 A EC SP13012770A
Authority
EC
Ecuador
Prior art keywords
phenyl
piperidin
diamine
methyl
isopropoxi
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Lili Feng
Piotr Karpinski
Baoqing Gong
Liladhar Murlidhar Waykole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP13012770A publication Critical patent/ECSP13012770A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ECSP13012770 2010-12-17 2013-07-16 Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina ECSP13012770A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17

Publications (1)

Publication Number Publication Date
ECSP13012770A true ECSP13012770A (es) 2013-10-31

Family

ID=45464892

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012770 ECSP13012770A (es) 2010-12-17 2013-07-16 Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina

Country Status (36)

Country Link
US (2) US9309229B2 (enExample)
EP (3) EP2651918B1 (enExample)
JP (1) JP5916752B2 (enExample)
KR (4) KR20180032680A (enExample)
CN (7) CN106831716A (enExample)
AR (2) AR084309A1 (enExample)
AU (1) AU2011343775B2 (enExample)
BR (1) BR112013015000A2 (enExample)
CA (1) CA2821102C (enExample)
CL (1) CL2013001723A1 (enExample)
CO (1) CO6801792A2 (enExample)
CY (2) CY1119474T1 (enExample)
DK (2) DK3121171T3 (enExample)
EC (1) ECSP13012770A (enExample)
ES (3) ES2696526T3 (enExample)
GT (1) GT201300153A (enExample)
HR (2) HRP20171477T1 (enExample)
HU (1) HUE041845T2 (enExample)
IL (1) IL226474A (enExample)
LT (2) LT3121171T (enExample)
MA (1) MA34771B1 (enExample)
MX (1) MX338210B (enExample)
MY (2) MY177742A (enExample)
NZ (1) NZ610713A (enExample)
PE (1) PE20140698A1 (enExample)
PH (1) PH12013501254A1 (enExample)
PL (2) PL3121171T3 (enExample)
PT (2) PT2651918T (enExample)
RS (1) RS57771B1 (enExample)
RU (2) RU2599785C3 (enExample)
SG (2) SG190856A1 (enExample)
SI (2) SI2651918T1 (enExample)
TN (1) TN2013000216A1 (enExample)
TW (2) TWI576344B (enExample)
WO (1) WO2012082972A1 (enExample)
ZA (1) ZA201303599B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG190856A1 (en) * 2010-12-17 2013-07-31 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
CA2890006C (en) 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
HRP20201343T1 (hr) 2014-10-21 2020-11-27 Ariad Pharmaceuticals, Inc. Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (zh) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 色瑞替尼的晶型i及其制备方法
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (en) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2017016529A1 (en) 2015-07-28 2017-02-02 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (zh) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 色瑞替尼的晶型及其制备方法
WO2017158619A1 (en) 2016-03-15 2017-09-21 Natco Pharma Limited A modified process for the preparation of ceritinib and amorphous form of ceritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
JP7494435B2 (ja) * 2020-01-17 2024-06-04 シュエンジュウ バイオファーマシューティカル カンパニー リミテッド 未分化リンパ腫キナーゼの多環状阻害剤の結晶形態
TW202144329A (zh) * 2020-03-30 2021-12-01 大陸商江蘇亞虹醫藥科技股份有限公司 硝羥喹啉前藥的晶型、含其的醫藥組成物及其製備方法和應用
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PL2287156T3 (pl) * 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EA017405B9 (ru) * 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
NZ590601A (en) * 2006-12-08 2011-09-30 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
EP2190826A2 (en) * 2007-08-28 2010-06-02 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
MX2010010968A (es) 2008-04-07 2010-10-26 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
KR101860057B1 (ko) * 2008-05-21 2018-05-21 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
WO2010142766A2 (en) * 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
SG190856A1 (en) 2010-12-17 2013-07-31 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
WO2012082580A2 (en) 2010-12-17 2012-06-21 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
DK2651902T3 (en) 2010-12-17 2018-01-08 Reata Pharmaceuticals Inc TRICYCLIC PYRAZOLYL AND PYRIMIDINYL ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
US9566882B2 (en) 2014-11-21 2017-02-14 Tk Holdings Inc. Airbag module
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016090070A1 (en) 2014-12-04 2016-06-09 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2017016529A1 (en) 2015-07-28 2017-02-02 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
ES2643016T3 (es) 2017-11-21
EP3453708B1 (en) 2021-10-27
CO6801792A2 (es) 2013-11-29
TW201629021A (zh) 2016-08-16
LT2651918T (lt) 2017-10-10
TN2013000216A1 (en) 2014-11-10
ES2696526T3 (es) 2019-01-16
US9309229B2 (en) 2016-04-12
BR112013015000A2 (pt) 2016-08-09
EP3121171A1 (en) 2017-01-25
TWI576343B (zh) 2017-04-01
JP5916752B2 (ja) 2016-05-11
ZA201303599B (en) 2014-02-26
DK3121171T3 (en) 2018-12-10
EP2651918A1 (en) 2013-10-23
CA2821102A1 (en) 2012-06-21
CN104262324A (zh) 2015-01-07
PE20140698A1 (es) 2014-06-11
CY1119474T1 (el) 2018-04-04
KR102325775B1 (ko) 2021-11-12
PL2651918T3 (pl) 2017-12-29
CL2013001723A1 (es) 2013-12-27
PL3121171T3 (pl) 2019-01-31
RU2746159C2 (ru) 2021-04-08
US20160175305A1 (en) 2016-06-23
TWI576344B (zh) 2017-04-01
PT3121171T (pt) 2018-11-27
EP3453708B8 (en) 2022-03-16
MX2013006952A (es) 2013-07-15
SG10201510082XA (en) 2016-01-28
AR084309A1 (es) 2013-05-08
WO2012082972A1 (en) 2012-06-21
MA34771B1 (fr) 2013-12-03
GT201300153A (es) 2014-06-09
KR20130130022A (ko) 2013-11-29
CN114989139A (zh) 2022-09-02
MY177742A (en) 2020-09-23
CN106831716A (zh) 2017-06-13
HRP20181737T1 (hr) 2018-12-28
DK2651918T3 (en) 2017-10-23
TW201307299A (zh) 2013-02-16
RU2016136823A (ru) 2018-12-11
SI3121171T1 (sl) 2018-11-30
AU2011343775B2 (en) 2015-12-03
CY1121017T1 (el) 2019-12-11
SG190856A1 (en) 2013-07-31
KR20190022903A (ko) 2019-03-06
SI2651918T1 (sl) 2017-10-30
JP2013545812A (ja) 2013-12-26
ES2905973T3 (es) 2022-04-12
NZ610713A (en) 2014-10-31
PT2651918T (pt) 2017-10-17
EP3121171B1 (en) 2018-08-15
IL226474A (en) 2016-03-31
CA2821102C (en) 2019-06-11
CN112125884A (zh) 2020-12-25
KR20200039021A (ko) 2020-04-14
RU2016136823A3 (enExample) 2020-02-06
HRP20171477T1 (hr) 2017-11-17
RS57771B1 (sr) 2018-12-31
CN103282359A (zh) 2013-09-04
IL226474A0 (en) 2013-07-31
AR122395A2 (es) 2022-09-07
EP2651918B1 (en) 2017-07-12
LT3121171T (lt) 2018-11-12
KR20180032680A (ko) 2018-03-30
US20130274279A1 (en) 2013-10-17
MX338210B (es) 2016-04-07
AU2011343775A1 (en) 2013-07-18
MY164810A (en) 2018-01-30
CN106008462A (zh) 2016-10-12
RU2599785C2 (ru) 2016-10-20
PH12013501254A1 (en) 2016-07-29
CN107056751A (zh) 2017-08-18
EP3453708A1 (en) 2019-03-13
RU2599785C3 (ru) 2019-04-24
HUE041845T2 (hu) 2019-05-28
RU2013132947A (ru) 2015-01-27

Similar Documents

Publication Publication Date Title
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
MX351507B (es) Composiciones farmaceuticas de co- cristales de tramadol y coxibs.
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY33735A (es) Compuestos antivirales
ECSP16093323A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
MX2020005645A (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido.
BR112014002922A2 (pt) compostos da fórmula i, processo de preparação de compostos da fórmula i, compostos da formula xii, viii e xi, composições agroquímicas, uso e semente
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
MX2015008233A (es) Nuevos derivados de quinolona.
CR20120287A (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2017000101A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
EA201300388A1 (ru) Соединения замещенного бензамида
ECSP14013215A (es) Compuestos novedosos
CR20140553A (es) Compuestos de fenoxietil piperidina
CR20140554A (es) Compuestos de acido dimetil-benzoico
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
CO7141413A2 (es) Proceso para la preparación de derivados de 2-(1-hidroxi-alquil)-cromen-4-ona ópticamente puros y opcionalmente sustituidos y su uso en la preparación de compuestos farmacéuticos
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола